Ocugen Announces Results Of The Partner’s New Covid Vaccine Booster Test Were Positive

Ocugen, a biopharmaceutical company, is focused now on developing a vaccine to fight COVID-19. As you may know, last year, it was proclaimed that Ocugen had collaborated with Bharat Biotech for the latter’s COVID 19 vaccine Covaxin, causing the stock to skyrocket. Ocugen was supposed to be in charge of advancing the vaccine’s development in Canada and the United States, according to the partnership’s terms. And on January 8, the company has announced the satisfied news related to the increased dose of the vaccine developed by its partner Bharat Biotech. It is reported that people who received an increased dose of Covaxin had significant immune changes.

More importantly, regulators have not yet approved persuasions in the United States or Canada. But there is still hope that Ocugen can get permission for emergency use from the US Food and Drug Administration (FDA). Separately, the company said studies on the effectiveness of Covaxin on the Omicron variant are ongoing, and results will be released shortly. Regardless, at the time of writing, the stock price is recovering well to $4.1550 by a 2% profit after its sharp drop of 13%.